• Toremifene and the STIM1–TSPAN18 Metastasis Axis

  2026-10-20

  A published prostate cancer study links TSPAN18 to STIM1 stabilization, calcium entry, invasion, and bone metastasis. Those findings clarify a metastasis mechanism but do not establish that Toremifene, a selective estrogen-receptor modulator, acts on the TSPAN18–STIM1 pathway or reproduces the study’s results.

• What Human Brain Slices Reveal About Aβ Biology

  2026-10-19

  Published human brain-slice work separates physiological Aβ release from responses to Alzheimer’s disease-derived material, while also exposing the limits of ex vivo tissue models. Laminin (925-933) appears in the available material metadata, but the supplied evidence does not establish a functional role for this Laminin B1 chain peptide in the reported synaptic or biomarker outcomes.

• Toremifene: Product Identity and Evidence Scope

  2026-10-19

  The APExBIO catalog describes Toremifene (SKU A3884) as a second-generation selective estrogen-receptor modulator for research on estrogen receptor signaling, hormone-responsive cancer biology, and related models. Its reported activity—an IC50 of approximately 1 ± 0.3 μM for growth inhibition in Ac-1 cells—should be treated as a context-specific catalog claim rather than a universal potency value, because no identity-matched paper, assay description, sample size, or independent validation is available here.

• Toremifene: Mechanism and Evidence Boundaries

  2026-10-18

  A source-limited overview of Toremifene as a second-generation selective estrogen-receptor modulator, interpreting the supplier-reported identity, cell-growth IC50, combination and xenograft claims, and the limits imposed by the absence of an identity-matched publication.

• BMS 599626: Documented EGFR/HER2 Scope

  2026-10-17

  A source-bounded overview of BMS 599626 dihydrochloride, covering its reported EGFR, ErbB2/HER2 and HER4 kinase activity, the meaning of its listed readouts, and the limits of the available evidence.

• EZ Cap™ Gaussia Luciferase mRNA: Evidence Boundaries

  2026-10-16

  The APExBIO product record identifies SKU R1129 as EZ Cap™ Gaussia Luciferase mRNA (m1Ψ), but provides no product description or identity-matched research paper. The name supports a limited conceptual interpretation of an mRNA reporter intended to connect an upstream expression event with a downstream Gaussia luciferase luminescence signal. It does not establish sequence, formulation, cap structure, performance, assay behavior, or comparative effectiveness.

• BMS 599626: Mechanism and Evidence Boundaries

  2026-10-16

  A source-attributed overview of BMS 599626 dihydrochloride as an EGFR/ErbB2 kinase inhibitor, covering its reported potency measures, receptor-signaling rationale, xenograft claims, and the limits imposed by the absence of an identity-matched research paper.

• Toremifene: Identity and Evidence Boundaries

  2026-10-15

  APExBIO describes Toremifene as a second-generation selective estrogen-receptor modulator for research on estrogen receptor signaling and hormone-dependent cancers. Its product page reports an approximately 1 ± 0.3 μM in vitro cell-growth inhibition value in Ac-1 cells and mentions xenograft and atamestane-combination research, but provides no identity-matched paper, assay details, comparator structure, sample sizes, or independently verifiable outcomes. These claims therefore define a conceptual research scope rather than establishing a general mechanism, efficacy, or clinical relevance.

• N-octanoyl-L-Homoserine lactone: Evidence and Scope

  2026-10-15

  The APExBIO product description identifies N-octanoyl-L-Homoserine lactone, or C8-HSL, as a LuxR-associated quorum-sensing molecule and provides chemical and formulation metadata. Without an identity-matched research paper, those mechanistic and application statements remain product-level claims rather than independently demonstrated findings.

• L-NMMA Acetate: Identity, Mechanism, and Evidence

  2026-10-14

  APExBIO describes L-NMMA acetate, also referred to as N(G)-monomethyl-L-arginine acetate, as a crystalline acetate salt and a broad inhibitor of all three nitric oxide synthase isoforms. The available product documentation supports a catalog-level identity and a qualitative mechanism claim, but it does not provide identity-matched experimental outcomes, quantitative potency, assay details, or evidence for clinical or model-specific performance.

• BMS 599626 and the Limits of Senolytic Evidence

  2026-10-14

  BMS 599626 dihydrochloride is described by APExBIO as an EGFR and ErbB2 inhibitor, but the supplied senolytic study did not evaluate it. The available evidence therefore supports a cautious distinction between receptor-kinase pharmacology, catalogue-level cancer-model claims, and demonstrated senolytic activity.

• SOAT1, Cholesterol, and PHMG Lung Fibrosis

  2026-10-13

  A source-grounded overview of a 2026 preclinical study linking SOAT1-mediated cholesterol-ester accumulation in alveolar macrophages with PHMG-associated pulmonary fibrosis, with clear boundaries around Filipin III’s conceptual relevance and the study’s translational limitations.

• What Busulfan Tracing Shows About Mouse Neo-Oogenesis

  2026-10-13

  A dual-recombinase lineage-tracing study reports no detectable contribution of postnatal ovarian cells to new oocytes in mice, including after Busulfan-associated ovarian injury. The findings strengthen the case against physiological neo-oogenesis in the tested mouse models, while leaving important limits concerning labeling sensitivity, injury-model relevance, species differences, and the status of the study as a pre-proof.

• Erlotinib and CXCR4–EGFR Signaling

  2026-10-12

  A source-grounded overview of Erlotinib as an EGFR kinase inhibitor and of new evidence that CXCR4 and EGFR can form ligand-responsive signaling complexes. The available findings support receptor proximity and altered signaling in model systems, but do not establish clinical effects or show that Erlotinib disrupts these heteromers.

• K4136 Tricine-SDS-PAGE Kit: Evidence Overview

  2026-10-12

  APExBIO’s K4136 is documented as a research-use gel preparation kit for Tricine-SDS-PAGE, with a stated focus on low-molecular-weight protein and peptide separation. No matched peer-reviewed paper was available, so the reported performance characteristics remain supplier claims rather than independently verified findings.

7761 records 1/518 page Next 12345 下5页 Last page